Drugs

, Volume 16, Issue 3, pp 177–201 | Cite as

Econazole: A Review of its Antifungal Activity and Therapeutic Efficacy

  • R. C. Heel
  • R. N. Brogden
  • T. M. Speight
  • G. S. Avery
Evaluations on New Drugs

Summary

Synopsis: Econazole1 is a recently introduced imidazole antifungal agent which is very closely related structurally to another imidazole derivative, miconazole. For local application the nitrate salt of econazole is used, while in preliminary investigations of systemic use in a few patients econazole base has been administered orally or intravenously.

In uncontrolled studies in large numbers of patients, econazole nitrate has been administered topically in the treatment of dermatomycoses due to a wide variety of fungi, and vaginally in the treatment of vaginal candidosis; but it has not been compared with any other antifungal drug in controlled therapeutic trials in mycoses of the skin and has only been compared with nystatin in a few patients with vaginal candidosis. Until adequate comparative studies are done the relative place of econazole in the treatment of dermatomycoses and vaginal candidosis, compared with traditional antifungal agents and with other imidazole derivatives such as miconazole or clotrimazole, cannot be clearly stated.

Nevertheless, econazole nitrate is an effective antifungal drug. In dermatological studies about 90% of a large number of patients were cured, often after a relatively short treatment period (2 to 6 weeks, as occurs with other imidazole antifungal agents). The cure rate was only slightly lower (about 85%) in patients with severe mycoses of many years’ duration than in those whose infections were of more recent onset. In vaginal candidosis a 3-day treatment regimen using a 150mg suppository once daily was only slightly less effective (85% mycological cure rate) than a 15-day regimen using a 50mg dose (suppository or cream) once daily (90 % cure rate). A 3 to 5 day ‘higher’ dose regimen was slightly more effective than a standard 15-day 1 ‘Ecostatin’ (Squibb); ‘Epi-Pevaryl’, ‘Gyno-Pevaryl’, ‘Mycopevaryl’, ‘Pevaryl’ (Cilag-Chemie). regimen of nystatin vaginal inserts in a small group of patients with vaginal candidosis. The convenience of the higher-dose shorter term regimen would likely be an important advantage to most patients. Whether other agents useful in vaginal candidosis would be as effective as econazole were they to be used in this way, has not been determined.

Topical or intravaginal econazole nitrate has usually been well tolerated, side effects being limited to local irritation in about 1 to 4% of patients in most studies.

Pharmacodynamic Studies: In standard in vitro sensitivity tests econazole has been shown to have activity against a wide variety of dermatophytes, yeasts, actinomycetes, moulds and other fungi, as well as some Gram-positive bacteria. It did not have useful activity against Gram-negative bacteria. Addition of bovine serum to the culture medium did not alter the activity of econazole against Candida albicans or C. tropicalis but decreased its activity against other fungi. In standard laboratory resistance-induction tests no apparent changes occurred in the sensitivity of Candida albicans or Trichophyton mentagrophytes to econazole, but in vivo emergence of cross resistance of Candida albicans to 3 imidazole drugs (miconazole, econazole and clotrimazole) has been reported in 1 patient.

Although the exact mechanism of econazole’s antimicrobial activity has not been conclusively determined, like other imidazole antifungal drugs it appears to act primarily by disrupting cell membrane systems.

In in vivo tests in mice with experimental systemic candidosis, both oral and intraperitoneal econazole were ineffective. However, intramuscular econazole prevented death in mice receiving lethal doses of Coccidioides immitis. In guinea pigs with dermatophytic cutaneous lesions, oral econazole and oral griseofulvin were of similar efficacy. Applied topically in animal tests, econazole was effective in vaginal and cutaneous candidosis and in dermatophytic skin infections.

Pharmacokinetic Studies: Only limited studies have been done on the pharmacokinetic properties of econazole in man. From the few patients tested in such studies it appears that about 90% of topically applied econazole nitrate (as the cream) remains on the skin surface, occlusion only slightly increasing the extent of absorption. Following vaginal application of econazole nitrate cream about 3 to 7 % of the dose was absorbed. From studies of systemic administration in a few volunteers it appears that likely therapeutic serum concentrations of econazole can be achieved after oral or intravenous administration (of econazole base), but not after administration of rectal suppositories. Further studies are needed in man on the extent of absorption and subsequent disposition of econazole after both local and systemic administration.

Therapeutic Trials: Although econazole nitrate has been studied in a large number of patients in uncontrolled trials, there have been no controlled comparisons with any other anti-fungal agent in therapeutic trials in patients with dermatological mycoses, and only 1 comparison with nystatin in a few patients with vaginal candidosis. Nevertheless, many of the uncontrolled studies were reasonably well designed, and used mycological and / or microscopical methods as well as clinical symptoms for diagnosis and evaluation of treatment. In such studies econazole nitrate appeared to be an effective agent for the topical treatment of dermatomycoses and vaginal candidosis; but until comparative studies have been done its relative place in the treatment of mycoses, compared with the traditional antimycotic agents and with other imidazole derivatives, cannot be clearly stated. In preliminary investigations, a few patients with ‘deep’ mycoses have been treated with oral or intravenous econazole (as the base), but its efficacy when used in this manner requires further study.

In patients with vaginal candidosis (econazole has not been studied in and is not recommended for treatment of trichomoniasis) 2 dosage regimens have been used: a 3-day treatment course using a 150mg vaginal suppository daily, or a 14 to 15 day course using a 50mg (suppository or cream) dose each day. The response rate to the short term regimen was only slightly less than to the longer regimen after 1 treatment course (85 and 90 % mycological cures, respectively), and after 2 treatment courses (in patients not responding to the first course) the overall mycological response rates were nearly identical (93 to 94%).

In the only study in which econazole was compared with another antifungal agent, a 3 to 5 day ‘higher’ dose (150mg suppository) regimen of econazole and a standard regimen of nystatin (a 100,000 unit vaginal tablet daily for 15 days) produced similar results in a small group of patients, although the response rate to econazole tended to be slightly higher.

The mycological response rate to econazole did not appear to be affected by the concomitant use of oral contraceptives, but in several studies pregnant women responded less frequently (about 78 %) than nonpregnant patients (about 88 %). Patients with positive rectal cultures on initiation of therapy had a lower response rate (71 %) than those with negative rectal cultures (90 % ) in 1 study. Symptomatic relief of vaginal burning and pruritus appeared to occur rapidly in most patients but vaginal discharge was relieved in a lesser proportion, and was less favourably influenced by the short term treatment regimen (relief in 42 to 96 % and 71 to 100 % of patients with short and longer term regimens, respectively). The rate of relapse and / or reinfection 4 weeks after completing a successful course of treatment with econazole appears to be about 10 %. Whether or not concurrent treatment of the patient’s sex partner with topical econazole has any influence on the relapse rate cannot be stated from present studies, as the results in patients in which this was done were not reported separately.

In dermatomycoses, and in a smaller number of patients with otomycoses, due to a wide variety of fungi, econazole has resulted in an overall clinical cure rate of about 90 %. Only a few patients with onychomycosis have been studied, and the response of this condition to econazole cannot be clearly stated. In most studies mycological tests were performed in addition to clinical evaluation, the reported mycological cure rate usually being 80 to 100 %. Recent and long standing mycoses seemed to respond nearly equally, the response rate in patients with severe chronic (10 to 30 years’ duration) infections in 1 study being only slightly less (85 %) than in patients with more recent infections (90 %). Some authors have reported that neither the infecting organism, the site of infection, nor the dosage form of econazole used affected the overall cure rate, but in other studies Candida albicans and Malassezia furfur (Pityrosporum orbiculare) infections responded slightly less frequently than those due to dermatophytes, and in 1 large study mycoses of the palms of the hands responded less often than those in other areas.

The onset of response of dermatomycoses to econazole treatment was usually fairly rapid, cures often being achieved in 2 to 6 weeks, although in 1 study inguinal mycoses required a longer duration of treatment to achieve a cure (average 16 weeks) than those in other areas.

Only a small number of patients with Gram-positive bacterial skin infections have been treated, the response rate varying from 54 % (pure bacterial infection) to 80 % (mixed bacterial / fungal infection).

Side Effects: Topical or intravaginal econazole nitrate has been well tolerated in most patients. When side effects occurred (about 1 to 4 % of patients in most studies) they involved irritation, redness, burning or itching. In dermatological studies they appeared to occur most frequently when econazole lotion was applied to the inguinal area. Discontinuing treatment due to adverse effects was necessary in about 1 to 2 % of dermatological patients, and only in isolated instances in patients with vaginal candidosis.

Dosage and Administration: In dermatomycoses a topical preparation of econazole should be applied twice daily (morning and evening), treatment continuing for several weeks (possibly with econazole powder) after the symptoms have disappeared.

In patients with vaginal candidosis, econazole may be administered in a short term regimen using a 150mg vaginal suppository inserted as high into the vagina as possible once daily for 3 days; or a longer regimen using a 50mg suppository or 1 applicator full of econazole vaginal cream inserted deeply into the vagina once daily for 15 days, regardless of whether the symptoms disappear sooner. (In some countries an initial treatment course of 7 days is recommended when the vaginal cream is used, to be followed by a second course if necessary.) In both regimens, treatment of the vulva and / or the prepuce and glans penis of the patient’s sex partner may be undertaken with econazole topical cream, applied twice daily after washing with warm water.

Keywords

Clotrimazole Econazole Pityriasis Versicolor Vaginal Suppository Vaginal Cream 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amblard, P.: L’econazole et le traitement des mycoses en dermatologie. Revue Medicale des Alpes Francaises 6: 41 (1977).Google Scholar
  2. Ansehn, S.: In vitro synergistic action of antimycotics and antibiotics on Candida albicans. Current Therapeutic Research 22: 92 (1977).Google Scholar
  3. Ansehn, S. and Winblad, B.: Surface morphology of Candida albicans after treatment with antimycotic drugs. Mykosen, Suppl. 1: 322 (1978).Google Scholar
  4. Aron-Brunetiere, R.; Dompmartin-Pernot, D. and Drouhet, E.: Treatment of pityriasis capitis (dandruff) with econazole nitrate. Acta Dermatovener (Stockholm) 57: 77 (1977).Google Scholar
  5. Balmer, J.A.: Vaginale Candidiasis und ihre Behandlung mit Econazol. Ars Medici 66: 195 (1976a).Google Scholar
  6. Balmer, J.A.: Three-day therapy of vulvovaginal candidiasis with econazole: A multicentric study comprising 996 cases. American Journal of Obstetrics and Gynecology 126: 436 (1976b).PubMedGoogle Scholar
  7. Bambule, J. and Grigoriu, D.: Les Otomycoses. Bulletin de la Societe de Mycologie Medicale 6: 71 (1977).Google Scholar
  8. Bambule, J. and Grigoriu, D.: Otomycoses and their treatment. Mykosen, Suppl. 1: 82 (1978a).Google Scholar
  9. Bambule, J. and Grigoriu, D.: Fungal nasosinusitis treated with econazole. Mykosen, Suppl. 1: 87 (1978b).Google Scholar
  10. Bardiaux, M.; Bonhomme, J.; Crimail, Ph.; Darmon, M.; Guillaumin, J.-P.; Julien-Laferriere, P.; Le Lievre, H.; Le Louet, J.M.; Leroy, B.; Martin-Dupray, D. and Torre, M.-Ph.: Nouvel apport dans le traitement des mycoses vulvo-vaginales: L’econazole. Semaine des Hopitaux de Paris Therapeutique 52: 493 (1976).Google Scholar
  11. Beeguer, J.: Un traitement de trois jours des candidiases vaginales. Medecine et Hygiene 34: 1925 (1976).Google Scholar
  12. Cameron, B.D.; Chasseaud, L.F.; Conway, B.; Fox, N. and Taylor, T.: Absorption and disposition of econazole nitrate after application to the skins and vaginas of rabbits. Arzneimittel-Forschung 26: 2054 (1976).PubMedGoogle Scholar
  13. Cartwright, R.Y.: Absorption of econazole from the human gastrointestinal tract. Current Chemotherapy, p.231 (1978).Google Scholar
  14. Dean, A.V.; Law, S.J.; Kripalani, K.J. and DiFazio, L.T.: Metabolism of 14C-econazole nitrate in monkeys. Federation Proceedings 36: 398 (1977).Google Scholar
  15. Dompmartin, D.; Drouhet, E. and Moreau, F.: Nouvelle enquete sur tinea imbricata (tokelau) et autres epidermomycoses tropicales en Oceanie (Iles Nouvelles-Hebrides et Banks); Resultats favourables avec un nouvel antifongique, econazole’, en traitement local. Bulletin de la Societe Francaise de Dermatologie et de Syphiligraphie, Paris 82: 422 (1975).Google Scholar
  16. Dorn, M.; Scherwitz, Chr.; Lentze, I. and Plewig, G.: Econazol-Nitrat. In-vitro-Testung und klinische Prufung. Munchener Medizinische Wochenschrift 117: 687 (1975).PubMedGoogle Scholar
  17. Drouhet, E. and Dupont, B.: Preliminary studies on the pharmacology and therapeutic activity of oral and intravenous econazole. Mykosen, Suppl. 1: 192 (1978).Google Scholar
  18. Eichmann, Th.: Lokale Behandlung von Pilzaffektionen der Haut mit Econazol, einem neuen Breitspektrum-Antimykotikum. Erfahrungsbericht. Schweizerische Rundschau fur Medizin (Praxis) 63: 719 (1974).Google Scholar
  19. Garrel, J.; Millet, P.; Jeanney, J.C. and Jacquelin, R.: Un nouvel antimycosique d’action polyvalente: l’econazole. Medecine et Armees 4: 5 (1976).Google Scholar
  20. Gisslen, H.; Hersle, K.; Mobacken, H. and Nordin, P.: Topical treatment of dermatomycoses and tinea versicolor with econazole cream 1 % (Pevaryl). Current Therapeutic Research 21: 681 (1977).Google Scholar
  21. Grigoriu, D.: Aspects cliniques, histologiques et therapeutiques du pityriasis versicolor. Bulletin de la Societe de Mycologie Medicale 6: 25 (1977).Google Scholar
  22. Guez, C.; Tourne, C.E.; Ritter, J. and Gandar, R.: Etude de l’action du Gyno-Pevaryl sur les mycoses genitales. Medecin du Nord et de l’Est No. 11, Nov. 1st (1976).Google Scholar
  23. Hantschke, D.; Schulte, R.; Dabag, S. and Greschuna, D.: Treatment with econazole of a case of pulmonary aspergillosis. Mykosen, Suppl. 1: 230 (1978).Google Scholar
  24. Hempel, M.: Klinische Erfahrungen in der lokalen Behandlung von Dermatomykosen mit Econazol-Hautmilch. Mykosen 18: 213 (1975).PubMedCrossRefGoogle Scholar
  25. Holt, R.J.: Topical pharmacology of imidazole antifungals. Journal of Cutaneous Pathology 3: 45 (1976).PubMedCrossRefGoogle Scholar
  26. Holt, R.J. and Azmi, A.: Miconazole-resistant Candida. Lancet 1: 226 (1978).Google Scholar
  27. Hur, M. and Kim, D.H.: The clinical effects of econazole nitrate vaginal suppository for candidal vaginitis. Journal of Research Institute of Medical Science of Korea 9: 71 (1977).Google Scholar
  28. Huriez, Cl. and Thomas, P.: Le Pevaryl en dermatologie (a propos de 30 observations). Lille Medicale 22 (Suppl.): 272 (1977).Google Scholar
  29. Itani, Z.S.: Uber die Zunahme der Mykosen in Deutschland. Erfahrungen mit dem neuen Breitband-Antimykotikum Econazol. Zeitschrift fur Hautkrankheiten 49: 683 (1974).PubMedGoogle Scholar
  30. Itani, Z.S.: Die Behandlung der Otomykosen mit dem neuen Breitband-Antimykotikum Econazol. Mykosen 19: 247 (1976).PubMedCrossRefGoogle Scholar
  31. Keller, K.: Klinische Efahrungen mit dem neuen Antimykotikum Econazol. Schweizerische Rundschau fur Medizin (Praxis) 63: 722 (1974).Google Scholar
  32. Kern, R. and Zimmermann, F.K.: Uber den Wirkungs mechanismus des Antimyzetikum Econazol. Mykosen 20: 133 (1977).PubMedCrossRefGoogle Scholar
  33. Kern, R. and Zimmerman, F.K.: Physiological effects of econazole nitrate on yeast cells. Mykosen, Suppl. 1: 339 (1978).Google Scholar
  34. Kim, J.M.; Eun, H.C.; Lee, C.W. and Kim, H.S.: A study on therapeutic evaluation with econazole in patients with dermatomycoses and in vitro determination of minimal inhibitory concentration. Korean Journal of Dermatology 15: 9 (1977).Google Scholar
  35. Knusel, H.: Vulvovaginale Mykosen-Kurztherapie (3 Tage) mit Econazol. Geburtshilfe und Frauenheilkunde 37: 43 (1977).PubMedGoogle Scholar
  36. Lambert, D.; Chapuis, J.L. and Camerlynck, P.: Devant la frequence croissante des mycoses cutanees. Action de Pevaryl en dermatologie, premier resultats. Lyon Medicale 237: 353 (1977).Google Scholar
  37. Lambotte, R.; Dogniez, B. and Sandront-Degee, M.: Influence of rectal infections caused by Candida albicans on the therapeutic results obtained in vaginal candidosis. Mykosen, Suppl. 1: 311 (1978).Google Scholar
  38. Levine, H.B.: R34000, a dioxolane imidazole in the therapy for experimental coccidioidomycosis. Chest 70: 755 (1976).PubMedCrossRefGoogle Scholar
  39. Lurie, D.: Die 3-Tage-Therapie der vaginalen Candidiasis. Therapeutische Umschau 34: 544 (1977).PubMedGoogle Scholar
  40. Mermet, D.; Long, B. and Saad-Zoy, R.: Une affection d’actualite: Les mycoses vulvo-vaginales, leur traitement par un nouveau fongicide: l’econazole. Lyon Medicale 237: 251 (1977).Google Scholar
  41. Netter, A.: Progres recents dans le traitement des candidoses vulvo-vaginales. Revue Francaise de Gynecologie et d’Obstetrique 72: 237 (1977).Google Scholar
  42. Obolensky, W. and Maire, F.: Die vulvo-vaginale Mykose und ihre Behandlung mit Econazol. Deutsche Medizinische Wochenschrift 100: 1730 (1975).PubMedCrossRefGoogle Scholar
  43. Pastel, A.; Taub, R. and Zara, A.: Nouvel abord therapeutique des mycoses cutaneomuqueuses. Semaine des Hopitaux de Paris Therapeutique 52: 549 (1976).Google Scholar
  44. Peios, E.: Lokalbehandlung von Soor-Kolpitis mit Econazol. Schweizerische Rundschau fur Medizin (Praxis) 64: 1261 (1975).Google Scholar
  45. Preusser, H.-J.: Die Wirkung von Econazol auf die Feinstruktur der Zellen von Trichophyton rubrum. Mykosen 18: 453 (1975).PubMedCrossRefGoogle Scholar
  46. Preusser, H.-J.: Effects of in vitro treatment with econazole on the ultrastructure of Candida albicans. Mykosen 19: 304 (1976).PubMedCrossRefGoogle Scholar
  47. Preusser, H.-J. and Roster, H.: Econazole effects on Trichophyton rubrum and Candida albicans — electron microscopic and cytochemical studies. Mykosen, Suppl. 1: 314 (1978).Google Scholar
  48. Privat, Y.: Face a la frequence croissante des mycoses cutanees. Un nouveau fongicide polyvalent: l’econazole. Semaine des Hopitaux de Paris Therapeutique 53: 153 (1977).Google Scholar
  49. Qadripur, S.A. and Bosse, K.: Econazol, ein neues Breitbandantimykotikum. Zeitschrift fur Hautkrankheiten 49: 769 (1974).PubMedGoogle Scholar
  50. Raab, W.: Clinical pharmacology of modern topical broad-spectrum antimicrobials. Current Therapeutic Research 22: 65 (1977).Google Scholar
  51. Raab, W. and Gmeiner, B.: Interactions between econazole, a broad-spectrum antimicrobic substance, and topically active glucocorticoids. Dermatologica 153: 14 (1976a).PubMedCrossRefGoogle Scholar
  52. Raab, W. and Gmeiner, B.: Evaluation of econazole by Warburg assay; comparison with other antimicrobials. Mykosen 19: 238 (1976b).PubMedCrossRefGoogle Scholar
  53. Raab, W.P.: Glucocorticoids and antimicrobials. Mykosen, Suppl. 1: 304 (1978).Google Scholar
  54. Ruppen, M.: Therapie der Soorkolpitis mit Econazol. Schweizerische Rundschau fur Medizin (Praxis) 66: 86 (1977).Google Scholar
  55. Sawyer, P.R.; Brogden, R.N.; Pinder, R.M.; Speight, T.M. and Avery, G.S.: Miconazole: A review of its antifungal activity and therapeutic efficacy. Drugs 9: 406 (1975a).PubMedCrossRefGoogle Scholar
  56. Sawyer, P.R.; Brogden, R.N.; Pinder, R.M.; Speight, T.M. and Avery, G.S.: Clotrimazole: A review of its antifungal activity and therapeutic efficacy. Drugs 9: 424 (1975b).PubMedCrossRefGoogle Scholar
  57. Schaefer, H. and Stuttgen, G.: Absolute concentrations of an anti-mycotic agent, econazole, in the human skin after local application. Arzneimittel-Forschung 26: 432 (1976).PubMedGoogle Scholar
  58. Schaefer, H. and Stuttgen, G.: Biopharmaceutical problems in the treatment of superficial mycoses. Mykosen, Suppl. 1: 164 (1978).Google Scholar
  59. Schar, G.; Kayser, F.H. and Dupont, M.C.: Antimicrobial activity of econazole and miconazole in vitro and in experimental candidiasis and aspergillosis. Chemotherapy 22: 211 (1976).PubMedCrossRefGoogle Scholar
  60. Scherwitz, C.: Klinische Prufung von Econazol Haut-Milch und -Creme bei Hautmykosen. Zeitschrift fur Hautkrankheiten 52: 117 (1977).PubMedGoogle Scholar
  61. Scherwitz, C. and Martin, R.: In vitro and in vivo ultrastructural changes in Pityrosporum orbiculare after treatment with econazole. Mykosen, Suppl. 1: 328 (1978).Google Scholar
  62. Schmid, P.: Klinische Erfahrungen bei der Behandlung von Hautmykosen mit Econazol-Creme und -Puder. Schweizerische Rundschau fur Medizin (Praxis) 63: 1156 (1974).Google Scholar
  63. Schwarz, K.J.; Much, Th. and Konzelmann, M.: Poliklinische Prufung von Econazol bei 594 Fallen von Hautmykosen. Deutsche Medizinische Wochenschrift 100: 1497 (1975).PubMedCrossRefGoogle Scholar
  64. Siboulet, A.: L’econazole spray-poudre en dermato-venereologie. Schweizerische Rundschau fur Medizin (Praxis) 65: 977 (1976).Google Scholar
  65. Thienpont, D.; van Cutsem, J.; van Nueten, J.M.; Niemegeers, C.J.E. and Marsboom, R.: Biological and toxicological properties of econazole, a broad-spectrum antimycotic. Arzneimittel-Forschung 25: 224 (1975).PubMedGoogle Scholar
  66. Vukovich, A.; Heald, A. and Darragh, A.: Vaginal absorption of two imidazole antifungal agents, econazole and miconazole. Clinical Pharmacology and Therapeutics 21: 121 (1977).Google Scholar
  67. Wenzel-Heiniger, K.: Beitrag zur Therapie der vulvovaginalen Mykosen. Schweizerische Rundschau fur Medizin (Praxis) 65: 287 (1976).Google Scholar
  68. Zimmermann, F.K.: The permeabilizing effect of econazole nitrate on yeast cells. 6th Congress ISHAM, Tokyo, June 29th–July 4th (1975).Google Scholar

Copyright information

© ADIS Press 1978

Authors and Affiliations

  • R. C. Heel
    • 1
  • R. N. Brogden
    • 1
  • T. M. Speight
    • 1
  • G. S. Avery
    • 1
  1. 1.Australasian Drug Information ServicesBirkenhead, Auckland 10New Zealand

Personalised recommendations